
FDA PCAC Recommends Six Peptide Groups for the 503A Bulks List
PCAC recommended six peptide-related substance groups for the Section 503A Bulks List on July 23–24, 2026. FDA final action remains pending.
Independent research library
Evidence-based explanations of peptide biology, clinical research, mechanisms, safety, and emerging compounds.
All articles cite primary scientific literature.

Selected evidence reviews and foundational research guides.

PCAC recommended six peptide-related substance groups for the Section 503A Bulks List on July 23–24, 2026. FDA final action remains pending.

How retatrutide, tirzepatide, and semaglutide differ in receptor targets, approval status, and Phase II/III weight-loss trial data — a side-by-side research comparison.

Retatrutide research: a GIP, GLP-1, and glucagon triple receptor agonist in Phase III trials, with Phase II data showing up to 24% weight loss at 48 weeks.

A research review of semaglutide, the GLP-1 receptor agonist marketed as Ozempic and Wegovy, covering its structural design, FDA-approved indications, landmark clinical trial data, and safety profile.

Research on GLP-1, GIP, and glucagon receptor agonists studied for metabolic health and weight management.
Research on peptides that stimulate growth hormone release through the pituitary-hypothalamic axis.
Research on melanocortin receptor peptides studied for pigmentation, sexual function, and anti-inflammatory effects.

Research on peptides studied for cognitive function, neuroprotection, and CNS effects.
FDA reviews, compounding policy, and evidence-based regulatory status for peptide-related bulk drug substances.

Core educational content explaining what peptides are, how they work, and how to evaluate research.
Research on peptides studied for skin regeneration, anti-aging, and cellular longevity.

Research on peptides studied for wound healing, connective tissue repair, and anti-inflammatory effects.

A favorable FDA PCAC recommendation for BPC-157 is not the same thing as the scientific literature on its mechanisms. Here's how the two evidence bases differ.

GHK-Cu and collagen peptides are both studied for skin health, but through very different mechanisms and evidence bases. Here's how the research compares.

A research overview of GLP-1 receptor agonist studies outside weight management, covering cardiovascular, kidney, liver, neurological, and reward-pathway research.

A foundational overview of the melanocortin receptor system (MC1R–MC5R) and why it is a research target for pigmentation, sexual function, and inflammation studies.

Melanotan II and PT-141 both act on melanocortin receptors, but differ sharply in receptor selectivity, evidence base, and regulatory status. Here's how they compare.

Selank is one specific research peptide within the much larger neuropeptide field. Here's how its evidence base compares to neuropeptide research as a whole.
Our articles are built from published research, clinical trial data, regulatory sources, and clearly cited scientific literature.
New research summaries and updated evidence, delivered to your inbox. No spam.